<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720431</url>
  </required_header>
  <id_info>
    <org_study_id>PMC_TTAC-0001_05</org_study_id>
    <nct_id>NCT03720431</nct_id>
  </id_info>
  <brief_title>TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer</brief_title>
  <official_title>A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmAbcine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmAbcine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to&#xD;
      establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in&#xD;
      combination with pembrolizumab in patients with metastatic triple-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">February 26, 2022</completion_date>
  <primary_completion_date type="Actual">March 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>During the first cycle (every cycle is 21 days) of treatment</time_frame>
    <description>The frequency and percentage of DLT will be presented by dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>The frequency and percentage of AEs will be presented by dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Presence anti-drug antibody (ADA) will be listed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)]</time_frame>
    <description>complete response (CR) or partial response (PR) by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)</time_frame>
    <description>complete response (CR), partial response (PR) or stable disease (SD) by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Period from the date of the drug administration to the disease progression time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Period from the date of the drug administration to the patient's death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Cmax</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Maximum concentration of drug by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Cmin</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Minimum concentration of drug by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - AUC0-t</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Area under the curve from baseline to each timepoint by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Tmax</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Time of Cmax by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - CL</measure>
    <time_frame>FFrom date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Clearance by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Vd</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Volume of distribution by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Ke</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Elimination rate constant by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - T½</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Half-life by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in concentration of serum angiogenic factor or receptor</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>VEGF, placental growth factor [PLGF], soluble vascular endothelial growth factor receptor [sVEGFR]-2, sVEGFR-1, etc.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-L1, VEGFR-2 expression level</measure>
    <time_frame>From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>PD-L1, VEGFR-2 expression level in tumour environment such as tumour, tumour vessel and parenchymal tissue</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TTAC-0001 and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTAC-0001 and pembrolizumab combination therapy will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTAC-0001 and pembrolizumab combination</intervention_name>
    <description>Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)&#xD;
Treatment groups: 3 dose levels&#xD;
Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1&#xD;
Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1&#xD;
Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1&#xD;
Cycle: 3 weeks (21 days per cycle)</description>
    <arm_group_label>TTAC-0001 and pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female and male patients ≥18 years old&#xD;
&#xD;
          2. Histologically proven metastatic breast carcinoma with triple negative receptor status&#xD;
             (Estrogen receptor, Progesterone receptor and human epidermal growth factor receptor 2&#xD;
             [HER2] negative) by IHC and Fluorescence in situ hybridization (FISH) according to&#xD;
             ASCO-CAP guideline3.&#xD;
&#xD;
          3. At least one confirmed measurable lesion by RECIST 1.1 criteria&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          5. A person who satisfies the following criteria in hematologic, renal, and hepatic&#xD;
             function tests performed within 7 days prior to screening:&#xD;
&#xD;
        (1) Hematologic tests&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
          -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
          -  Haemoglobin ≥ 9.0 g/dL (2) Blood coagulation tests&#xD;
&#xD;
          -  Prothrombin time (PT) ≤ 1.5 x Upper limit of normal (UNL)&#xD;
&#xD;
          -  Activated partial thromboplastin Time (aPTT) ≤ 1.5 x UNL (3) Hepatic function tests&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x UNL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x&#xD;
             ULN in case of liver metastasis) (4) Renal function test&#xD;
&#xD;
          -  ≤1.5 × ULN or creatinine clearance (CrCl) ≥30 mL/min for patient with creatinine&#xD;
             levels &gt;1.5 × institutional ULN 6) At least 12 weeks of expected life expectancy 7)&#xD;
             The patient (or legally acceptable representative if applicable) is able and willing&#xD;
             to provide written informed consent for the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 2 years. (Note: Patients with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma,&#xD;
             cervical cancer in situ) controlled by curative therapy are not excluded)&#xD;
&#xD;
          2. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Patients with previously treated brain metastases may participate provided&#xD;
             they are radiologically stable, i.e., without evidence of progression for at least 4&#xD;
             weeks by repeat imaging (note that the repeat imaging should be performed during study&#xD;
             screening), clinically stable and without requirement of steroid treatment for at&#xD;
             least 14 days prior to first dose of study treatment&#xD;
&#xD;
          3. Has a history of (non-infectious) pneumonitis/interstitial lung diseases that required&#xD;
             steroids or current pneumonitis/interstitial lung disease.&#xD;
&#xD;
          4. Has an active infection requiring systemic therapy&#xD;
&#xD;
          5. Uncontrolled hypertension (systolic blood pressure [SBP]&gt; 150 or diastolic blood&#xD;
             pressure [DBP]&gt; 90 mmHg)&#xD;
&#xD;
          6. Uncontrolled seizures&#xD;
&#xD;
          7. Class III or IV heart failure by New York Heart Association (NYHA) classification&#xD;
&#xD;
          8. Has oxygen-dependent chronic disease&#xD;
&#xD;
          9. Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar&#xD;
             disorder etc.). Treated depression with ongoing antidepressant medication is not an&#xD;
             exclusion&#xD;
&#xD;
         10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to&#xD;
             start of study drug&#xD;
&#xD;
         11. History of serious gastrointestinal haemorrhage within 6 months prior to start of&#xD;
             study drug&#xD;
&#xD;
         12. History of severe arterial thromboembolic event within 12 months of start of study&#xD;
             drug&#xD;
&#xD;
         13. Serious grade 4 venous thromboembolic event including pulmonary embolism&#xD;
&#xD;
         14. History of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
         15. History of posterior reversible encephalopathy syndrome&#xD;
&#xD;
         16. Planned surgery within 4 weeks post last dose&#xD;
&#xD;
         17. Moderate to severe proteinuria&#xD;
&#xD;
         18. Requiring therapeutic anticoagulation with warfarin at baseline&#xD;
&#xD;
         19. Not recovered below National Cancer Institute -Common Terminology Criteria for Adverse&#xD;
             Events (NCI-CTCAE) grade 1 or baseline from AEs due to previous therapy&#xD;
&#xD;
         20. Treatment with systemic chemotherapy, hormonal therapy, immunotherapy or biologic&#xD;
             therapy within 2 weeks prior to the baseline visit&#xD;
&#xD;
         21. Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
&#xD;
         22. Undergone major surgery requiring general anaesthesia or a respiratory assistance&#xD;
             device within 4 weeks prior to the baseline visit&#xD;
&#xD;
         23. Treated with other investigational drugs within 4 weeks prior to the baseline visit&#xD;
             for this study&#xD;
&#xD;
         24. Female who is pregnant* or lactating and of childbearing potential who does not agree&#xD;
             to a reliable and adequate method of contraception&#xD;
&#xD;
         25. A known history of severe drug hypersensitivity or hypersensitivity to a therapy&#xD;
             similar to the study drugs&#xD;
&#xD;
         26. Unable to participate in the trial according to the investigator's decision.&#xD;
&#xD;
         27. Previous therapy with vascular endothelial growth factor (VEGF)-targeted agents&#xD;
             including (but not limited to) bevacizumab&#xD;
&#xD;
         28. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,&#xD;
             CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or&#xD;
             higher irAE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollywood Private Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

